Lek Pharmaceuticals D.d.

Lovro Selic

Andreas Hotter

Ulrich Griesser

Christoph Langes

Nenad Maras

Samo Pirc

Anja Cusak

The present invention relates to processes for preparing substances with antiviral activity, in particular the integrase inhibitors dolutegravir and cabotegravir and analogues thereof, as well as intermediates useful in the processes.

Processes for preparing dolutegravir and cabotegravir and analogues thereof

The present invention relates to non-stoichiometric crystalline hydrates of 1-(&#x3b2;-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, processes for their preparation, and their use as medicaments. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel crystalline hydrates.

Crystalline hydrates of 1-(&#x3b2;-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene

A process for the preparation of a new crystal form of sunitinib malate, along with pharmaceuticals comprising the same are described.

Crystal form of sunitinib malate

Pharmaceutically acceptable salts of sunitinib, processes of making sunitinib salts, as well as related pharmaceuticals and methods of treating are described.

Salts of sunitinib

The present invention relates to a process for the preparation and purification of olmesartan medoxomil hydrohalide salts and optionally converting them to olmesartan medoxomil. The invention also relates to products obtainable by the process of the invention, to pharmaceutical compositions comprising the products and to their use in medicine, particularly to treat hypertension.

Process for the preparation or purification of olmesartan medoxomil

A process for the manufacturing of a pure irbesartan comprising converting irbesartan or a protected derivative thereof into an isolated hydrohalide acid addition salt, whereupon said hydrohalide acid addition salt is converted into the irbesartan is described.

Growing community of inventors

Ljubljana, Slovenia

Lovro Selic